Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Prediction of Drug Efficacy in Colon Cancer Preclinical Models Using a Novel Ranking Method of Gene Expression.

Fritz J, Lefebvre O, Fernandez A, Schmidt J, Bagnard D.

Cancers (Basel). 2020 Jan 8;12(1). pii: E149. doi: 10.3390/cancers12010149.

2.

Current drug design to target the Semaphorin/Neuropilin/Plexin complexes.

Meyer LA, Fritz J, Pierdant-Mancera M, Bagnard D.

Cell Adh Migr. 2016 Nov;10(6):700-708. Review.

3.

Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide.

Jacob L, Sawma P, Garnier N, Meyer LA, Fritz J, Hussenet T, Spenlé C, Goetz J, Vermot J, Fernandez A, Baumlin N, Aci-Sèche S, Orend G, Roussel G, Crémel G, Genest M, Hubert P, Bagnard D.

Oncotarget. 2016 Sep 6;7(36):57851-57865. doi: 10.18632/oncotarget.11072.

4.

Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis.

Arpel A, Sawma P, Spenlé C, Fritz J, Meyer L, Garnier N, Velázquez-Quesada I, Hussenet T, Aci-Sèche S, Baumlin N, Genest M, Brasse D, Hubert P, Crémel G, Orend G, Laquerrière P, Bagnard D.

Cell Rep. 2014 Sep 25;8(6):1714-1721. doi: 10.1016/j.celrep.2014.07.044. Epub 2014 Sep 15.

Supplemental Content

Loading ...
Support Center